Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTPN1 | P18031 | 1/20 | 0.35 |
| ▸ | HTR2C | P28335 | 1/20 | 0.31 |
| ▸ | HTR2A | P28223 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13199863 | 0.87 | PTPN1 (0.33) | PTPN1 | |
| SCHEMBL20804042 | 0.79 | HTR2A (0.31) | HTR2CHTR2A | |
| SCHEMBL84437 | 0.79 | — | — | |
| SCHEMBL12728724 | 0.79 | — | — | |
| SCHEMBL1054213 | 0.72 | — | — | |
| SCHEMBL20804079 | 0.71 | — | — | |
| SCHEMBL1053137 | 0.70 | — | — | |
| SCHEMBL9912449 | 0.69 | — | — | |
| SCHEMBL306894 | 0.69 | — | — | |
| SCHEMBL8384557 | 0.69 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023247593-A1 | PYRROLOPYRIDINE CARBOXAMIDES AND THEIR USES AS PDGFR INHIBITORS | ACTELION PHARMACEUTICALS LTD (CH) | 2023-12-28 | — | — | WO | disclosed |
| WO-2023247595-A1 | PYRAZOLOPYRAZINE CARBOXAMIDES AND THEIR USES AS PDGFR INHIBITORS | ACTELION PHARMACEUTICALS LTD (CH) | 2023-12-28 | — | — | WO | disclosed |
| US-20230021916-A1 | MODULATORS OF RHO-ASSOCIATED PROTEIN KINASE | REDX PHARMA LIMITED (GB) | 2023-01-26 | — | — | US | disclosed |
| US-11168093-B2 | Thienopyridine inhibitors of RIPK2 | CELGENE CORPORATION (US) | 2021-11-09 | — | — | US | disclosed |
| US-20210038606-A1 | Modulators of Rho-associated Protein Kinase | REDX PHARMA LIMITED (GB) | 2021-02-11 | — | — | US | disclosed |
| US-20200199148-A1 | THIENOPYRIDINE INHIBITORS OF RIPK2 | CELGENE CORPORATION | 2020-06-25 | — | — | US | disclosed |
| US-10640500-B2 | Tetrahydropyrazolopyrimidine compounds | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2020-05-05 | — | — | US | disclosed |
| US-10633350-B2 | Diphenyl derivatives and uses thereof | NOVARTIS AG (CH) | 2020-04-28 | — | — | US | disclosed |
| US-20190077773-A1 | DIPHENYL DERIVATIVES AND USES THEREOF | NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH, INC. | 2019-03-14 | — | — | US | disclosed |
| US-9850242-B2 | Tetrahydropyrazolopyrimidine compounds | EISAI R&D MANAGEMENT CO., LTD (JP) | 2017-12-26 | — | — | US | disclosed |
| US-8637500-B2 | Aminopyridine and carboxypyridine compounds as phosphodiesterase 10 inhibitors | AMGEN INC. (US) | 2014-01-28 | — | — | US | disclosed |
| US-20100160280-A1 | AMINOPYRIDINE AND CARBOXYPYRIDINE COMPOUNDS AS PHOSPHODIESTERASE 10 INHIBITORS | AMGEN INC. (US) | 2010-06-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200199148-A1 | THIENOPYRIDINE INHIBITORS OF RIPK2 | RIPK2, RIPK1, RIPK4 | PTPN1 2406/4885HTR2C 2538/4885HTR2A 1819/4885 |
| US-20190077773-A1 | DIPHENYL DERIVATIVES AND USES THEREOF | MYOF, NGF, MUSK | PTPN1 2224/4885HTR2C 4666/4885HTR2A 3862/4885 |
| US-10640500-B2 | Tetrahydropyrazolopyrimidine compounds | SSB, TLR8, TLR9 | PTPN1 117/4885HTR2C 1162/4885HTR2A 1400/4885 |
| US-20210038606-A1 | Modulators of Rho-associated Protein Kinase | ROCK2, ROCK1, RHOA | PTPN1 1095/4885HTR2C 3646/4885HTR2A 3285/4885 |
| US-10633350-B2 | Diphenyl derivatives and uses thereof | MYOF, NGF, MUSK | PTPN1 2224/4885HTR2C 4666/4885HTR2A 3862/4885 |
| US-11168093-B2 | Thienopyridine inhibitors of RIPK2 | RIPK2, RIPK1, RIPK4 | PTPN1 2406/4885HTR2C 2538/4885HTR2A 1819/4885 |
| US-20100160280-A1 | AMINOPYRIDINE AND CARBOXYPYRIDINE COMPOUNDS AS PHOSPHODIESTERASE 10 INHIBITORS | PDE4A, PDE7A, PDE4D | PTPN1 44/4885HTR2C 1935/4885HTR2A 1745/4885 |
| US-20230021916-A1 | MODULATORS OF RHO-ASSOCIATED PROTEIN KINASE | ROCK2, ROCK1, RHOA | PTPN1 1194/4885HTR2C 3799/4885HTR2A 3411/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.